Satellos Bioscience (NASDAQ:MSLE) Upgraded at Canaccord Genuity Group

Satellos Bioscience (NASDAQ:MSLE) was upgraded by equities researchers at Canaccord Genuity Group to a “moderate buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other brokerages have also recently weighed in on MSLE. Leerink Partners began coverage on shares of Satellos Bioscience in a research report on Monday, April 6th. They issued an “outperform” rating and a $20.00 price target for the company. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th. Wall Street Zen raised shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Monday, May 11th. Finally, Cantor Fitzgerald began coverage on shares of Satellos Bioscience in a research report on Wednesday, March 11th. They issued an “overweight” rating for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Satellos Bioscience Trading Down 5.5%

Satellos Bioscience stock opened at $6.75 on Thursday. The stock has a market cap of $140.60 million, a PE ratio of -4.22 and a beta of 1.60. The stock’s fifty day moving average price is $7.11. Satellos Bioscience has a 12-month low of $4.53 and a 12-month high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). On average, sell-side analysts expect that Satellos Bioscience will post -2.26 earnings per share for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.